antibody

Anti-Human HLA-DR, Biotin, (Clone YE2/36 HLK) (rat IgG2a)

MBS520340

0.1 mg

230 USD

monoclonal

rat

biotin

YE2/36 HLK

Antibody

Anti-Human HLA-DR, Biotin, (Clone YE2/36 HLK) (rat IgG2a)

HLA-DR

HLA-DR, Biotin, (Clone YE2/36 HLK) (rat IgG2a); Purified Anti-Human HLA-DR Monoclonal Antibody

HLA-DR; HLA-DR; HLA class II histocompatibility antigen, DQ beta 1 chain; MHC DQ beta; MHC class2 antigen; lymphocyte antigen; MHC class II antigen DQB1; MHC class II DQ beta chain; MHC class II antigen HLA-DQ-beta-1; MHC class II HLA-DQ beta glycoprotein; major histocompatibility complex, class II, DQ beta 1

HLA-DR

HLA-DQB1; IDDM1; CELIAC1; HLA-DQB

Q29900_HUMAN

Monoclonal

Rat IgG2a

YE2/36 HLK

Rat

Human

42

HLA-DR (HLA-DR Ia alpha chain, cross reactive with mouse H-2, I-A sub-region)

Biotin conjugated Ig buffered in PBS, 0.02% NaN3 and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. (Purified from ascites via Protein G Chromatography)

Antibody Concentration: 0.1 mg/ml

Store at 4 degree C. For long term storage, aliquot and freeze unused portions at -20 degree C, in volumes appropriate for single usage. Avoid freeze/thaw cycles.

Immunohistochemistry (IHC)

flow cytometry, immunofluorescence1 and immunohistochemistry3 (frozen and paraffin sections).

Immunogen: EHR-B Ramos cells. Donor: immunized AO rat spleen cells. Fusion Partner: Y3 Ag1.2.3 rat myeloma

Presentation: 100ug Biotin conjugated Ig buffered in PBS, 0.02% NaN3 and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml.

purified anti-human HLA-DR monoclonal antibody recognizes an epitope on the Ia alpha chain of the Human lymphocyte antigen. This antibody has also been shown to recognize the H-2, I-A region of the mouse.

642238

CAA23788.1

Q29900

5,068 Da

Adaptive Immune System Pathway (366160); Allograft Rejection Pathway (83123); Allograft Rejection Pathway (535); Antigen Processing And Presentation Pathway (83074); Antigen Processing And Presentation Pathway (485); Asthma Pathway (83120); Asthma Pathway (532); Autoimmune Thyroid Disease Pathway (83121); Autoimmune Thyroid Disease Pathway (533); Cell Adhesion Molecules (CAMs) Pathway (83069)

HLA-DQB1 belongs to the HLA class II beta chain paralogs. This class II molecule is a heterodimer consisting of an alpha (DQA) and a beta chain (DQB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and it contains six exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DQ molecule both the alpha chain and the beta chain contain the polymorphisms specifying the peptide binding specificities, resulting in up to four different molecules. Typing for these polymorphisms is routinely done for bone marrow transplantation. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2011]

HLA-DQB1: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. Belongs to the MHC class II family. Protein type: Membrane protein, integral. Chromosomal Location of Human Ortholog: 6p21.3. Cellular Component: Golgi membrane; membrane; lysosomal membrane; plasma membrane; trans-Golgi network membrane; endosome membrane; MHC class II protein complex. Molecular Function: MHC class II receptor activity; peptide antigen binding. Biological Process: humoral immune response mediated by circulating immunoglobulin; cytokine and chemokine mediated signaling pathway; T cell costimulation; antigen processing and presentation of exogenous peptide antigen via MHC class II; immune response; immunoglobulin production during immune response; T cell receptor signaling pathway. Disease: Celiac Disease; Creutzfeldt-jakob Disease; Multiple Sclerosis, Susceptibility To

0.1 mg

230 USD